PURPOSE: To investigate potential differences in pathological complete response (pCR) rates and overall survival (OS) between HER2-low and HER2-zero patients with early-stage hormone receptor (HR)-positive and triple-negative breast cancer (TNBC), in the n...
[10]Liedtke C, Mazouni C, Hess KR, et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol. 2008 Mar 10;26(8):1275-81. [11]Yau C, Osdoit M, van der Noordaa M, et al. Residual cancer burden after neoadjuvant chemo...
[3] Jun-Jie Li; Zhong-Hua Wang; Li Chen et al. HER2-Directed Antibody-Drug Conjugate SHR-A1811 in the Neoadjuvant Treatment of HER2-positive Early Breast Cancer: a Prospective, Randomized, Open-label, Phase 2 Trial. 2024 SABCS GS1-04. [4] Tomás Pascual, Kepa Amillano Parraga, Javier...
PURPOSE: To investigate potential differences in pathological complete response (pCR) rates and overall survival (OS) between HER2-low and HER2-zero patients with early-stage hormone receptor (HR)-positive and triple-negative breast cancer (TNBC), in the neoadjuvant chemotherapy setting. METHODS: We...
三阳性乳腺癌(triple-positive breast cancer,TPBC)是指雌激素受体(estrogen receptor,ER)、孕激素受体(progesterone receptor,PR)和人表皮生长因子受体2(human epidermal growth factor receptor 2,HER2)表达均为阳性的乳腺癌,占所有乳腺癌病理学类型的5%～10%[12]。...
3. Modi S, Jacot W, Iwata H, et al. 376O Trastuzumab deruxtecan (T-DXd) versus treatment of physician’s choice (TPC) in patients (pts) with HER2-low unresectable and/or metastatic breast cancer (mBC): Updated survival results of the randomized, phase III DESTINY-Breast04 study[J]....
Methods: This was a retrospective analysis of data from 1099 patients diagnosed with HER2/neu‐positive BC who were screened for germline BRCA mutations between 1996 and 2022. Clinicopathologic features and survival rates were analyzed by BRCA mutation status. Univariate and multivariable Cox ...
PURPOSE: To investigate potential differences in pathological complete response (pCR) rates and overall survival (OS) between HER2-low and HER2-zero patients with early-stage hormone receptor (HR)-positive and triple-negative breast cancer (TNBC), in the neoadjuvant chemotherapy setting. ...
CYB561 has higher expression and shorter survival in HER2-positive BRCA patients BRCA were separated into four kinds of molecular subtypes (Luminal A, Luminal B, HER2-positive, and triple-negative BRCA) using immunohistochemical surrogates for molecular classifications [18]. To investigate the function...
编者按:HER2低表达已成为乳腺癌诊疗的热点话题,随着国内外专家学者对新型ADC药物靶向治疗的探索,为HER2低表达乳腺癌患者带来新的曙光。在北京召开的2024全国乳腺癌大会上,复旦大学附属肿瘤医院张剑教授对新版指南中“HER2低表达晚期乳腺癌”的更新要点进行了介绍,会后《肿瘤瞭望》特邀张剑教授就相关内容进行深入解读。